What's in a Name? Why Words Matter in Advanced Prostate Cancer

William K Oh; Neeraj Agarwal; Alan Bryce; Pedro Barata; Courtney Bugler; Sigrid V Carlsson; Brad Cornell; William Dahut; Daniel George; Stacy Loeb; Bruce Montgomery; David Morris; Lorelei A Mucci; Aurelius Omlin; Ganesh Palapattu; Irbaz Bin Riaz; Charles Ryan; Martin W Schoen; Samuel L Washington 3rd; Silke Gillessen

doi:10.1016/j.eururo.2024.10.017

What's in a Name? Why Words Matter in Advanced Prostate Cancer

Eur Urol. 2024 Oct 28:S0302-2838(24)02680-0. doi: 10.1016/j.eururo.2024.10.017. Online ahead of print.

Authors

William K Oh¹, Neeraj Agarwal², Alan Bryce³, Pedro Barata⁴, Courtney Bugler⁵, Sigrid V Carlsson⁶, Brad Cornell⁷, William Dahut⁸, Daniel George⁹, Stacy Loeb¹⁰, Bruce Montgomery¹¹, David Morris¹², Lorelei A Mucci¹³, Aurelius Omlin¹⁴, Ganesh Palapattu¹⁵, Irbaz Bin Riaz¹⁶, Charles Ryan¹⁷, Martin W Schoen¹⁸, Samuel L Washington 3rd¹⁹, Silke Gillessen²⁰

Affiliations

¹ Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: william.oh@mssm.edu.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address: neeraj.agarwal@hci.utah.edu.
³ Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, AZ, USA.
⁴ University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁵ Zero Prostate Cancer, Washington, DC, USA.
⁶ Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden.
⁷ Patient advocate.
⁸ American Cancer Society, Atlanta, GA, USA.
⁹ Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
¹⁰ Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY, USA.
¹¹ Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Fred Hutchinson Cancer Center, Seattle, WA, USA.
¹² Urology Associates PC, Nashville, TN, USA.
¹³ American Cancer Society, Atlanta, GA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
¹⁴ Onkozentrum Zürich und Uroonkologisches Zentrum, Hirslanden Zürich, Zurich, Switzerland.
¹⁵ Department of Urology, University of Michigan, Ann Arbor, MI, USA.
¹⁶ Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA.
¹⁷ Zero Prostate Cancer, Washington, DC, USA / University of Minnesota, Minneapolis, MN, USA.
¹⁸ Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO, USA.
¹⁹ Department of Urology, University of California-San Francisco, San Francisco, CA, USA.
²⁰ Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

PMID: 39472202
DOI: 10.1016/j.eururo.2024.10.017

Abstract

Much of the disease nomenclature used for patients with advanced prostate cancer has negative connotations and can be confusing or intimidating. Experts in the field convened to recommend a clearer and more accurate approach to defining the nomenclature.

Publication types

Editorial